Tengzhou Central People's Hospital Report issue

Academic/Hospital Phase 3

Organization Overview

First Clinical Trial
2015
NCT03157401
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Tengzhou Central People's Hospital

Active Ingredients

Drugs in Phase 3 Trials (3)

epirubicin (ellence) (1 trial)

gelatin (1 trial)

lipiodol (1 trial)

Drugs in Other Trials (1)

tranexamic acid (cyklokapron) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma, Hepatocellular (Phase 3)

Thrombosis (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 4